Introduction
Though the incidence of jaundice after exposure to halothane is believed to be low, concern remains for the safety of patients who may be exposed to halothane several times within a short period. Apart from nitrous oxide and possibly thiopentone, halothane is the most widely used of all the anaesthetics, and an increasing number of patients have been exposed to it more than once. Of some 850,000 patients included in the American National Halothane Study (National Research Council, 1969) 9% were estimated to have been exposed to it more than once within a 28-day period. Mushin et al. (1971) , in a study of 558 unselected surgical patients in three South Wales hospitals, found that 7\ had been similarly exposed. In this paper we attempt to identify at least one of the many possible factors associated with jaundice after exposure to halothane or other anaesthetic vapours. Since thiopentone and nitrous oxide are commonplace as adjuncts to anaesthesia with other agents no separate analysis for them is possible. 
Material and Methods
The study was based on 130 reports of jaundice attributed to halothane received by the Committee on Safety of Medicines* during January 1964 to December 1972. About half of the patients were included in the earlier analysis by Mushin et al. (1971) . In 17 of these reports other anaesthetics apart from thiopentone and nitrous oxide had also been used. In one, for example, a patient was noted to have received at various times propanidid, trichloroethylene, and methoxyflurane in addition to halothane. Another patient had been anaesthetized with methohexitone on six occasions for electric convulsion therapy. In the nine-year period, however, no report attributed jaundice to any other anaesthetic agent.
We grouped the reports according to the number of exposures to halothane (table I) . With the exception of 1964, when reports were received during only part of the year, the number of adverse reactions reported each year had been fairly consistent, suggesting that the reporting rate had not been influenced to any large extent by publications on the potential toxicity of halothane (table II) .
Results

ONE EXPOSURE
Altogether 20 patients were reported to have developed jaundice after a single exposure to halothane (table III) . Their ages ranged from 13 to 76 years (mean 49-2 + S.D. 18-1 years). Seven (35",,) died from hepatic failure. One patient (case 4) gave a history of alcoholism, and another (case 15) had been started on rifampicin three days after exposure to halothane. In this case the jaundice soon cleared and she was subsequently anaesthetized a second time with halothane without incident. One patient (case 18) had been anaesthetized with trichloroethylene six months previously and developed jaundice two days after the use of halothane. Jaundice occurred within 28 days of exposure to halothane in all 20 cases. The exact interval between exposure and onset was recorded in 17 (mean interval 1 1 7 days). The three remain-*1 ormerlv the Committee on Safetv of Drugs. The differences between patients exposed twice, three times, and four or more times were not statistically significant.
In multiple-exposure cases the interval between the most recent exposure and the onset of jaundice did not appear to depend on the length of the period between exposures. The mean interval in 22 patients exposed two to six times over a period of more than 28 days was 6-1 days. In 59 patients exposed over a period of less than 28 days the mean interval was 5-8 days. (National Research Council, 1969) in the U.S.A. halothane had been used in some 30") of 850,000 procedures. There were 82 necropsy diagnoses of acute hepatic failure and a panel of experts attributed 73 of these to postoperative complications, leaving only nine deaths unexplained. Seven of the nine patients had received halothane but the mortality from all causes of death after halothane anaesthesia of 1-87", did not differ from the mortality of 193 associated with other anaesthetic agents.
Mushin et al. (1971) estimated that the risk of jaundice among patients exposed to halothane more than once within a four-week period seemed to lie between 1 in 6,000 and 1 in 20,000.
There is now fairly general agreement that out of several possible factors multiple exposure to halothane has been a common one. In view of the frequent accounts of jaundice occurring after two or more exposures to halothane it appears to be undesirable to rechallenge any patient who has recently been exposed to halothane unless there is an overriding clinical indication.
In this paper the main objective has been to study the time relationship of anaesthetic procedures in patients reported to have developed jaundice after exposure to halothane or other agents and to search for trends which could not be explained by selective or biased reporting to the Committee on Safety of Medicines. The available data are drawn from voluntary reports to the committee's Register of Adverse Reactions.
The principal findings based on 114 patients in this study who had complete anaesthetic histories (tables III-VI) were as follows: (a) 94 (821 ) of the reports described patients who had been exposed to halothane more than once; (b) of these 94 patients, for thom the interval between exposures was known, 75 (80") had received halothane more than once within a 28-day period; (c) the proportion of reports in which the outcome was fatal increased with age and the number of exposures (see table I ); (d) the interval between the second or subsequent exposure and the onset of jaundice was significantly shorter than the interval after a single exposure; and (e) the reports to the committee do not attribute a causal connexion with any anaesthetic agent other than halothane. It is likely that the reports are highly selected. Many anaesthetists are aware of the possibility that jaundice is more likely to occur after repeated exposures to halothane at short intervals, and reporting bias could influence the first and second of the above findings. Doctors may also have reported fatal events more completely than non-fatal ones. It is difficult, however, to understand how reporting bias could have accounted for the fourth finding-that the interval between exposure to halothane and the onset of jaundice is shorter when there has been more than one exposure. This strongly suggests that earlier exposure to halothane predisposes to some form of sensitivity in certain patients. When jaundice developes late the patient is more likely to have been discharged from hospital and the event is thus perhaps less likely to be reported, because the doctor to whose care the patient has been transferred may not be aware that halothane has been used. This could lead to relative underreporting of jaundice after single exposure (where the interval has been shown to be longer) but could not account for the significant difference that has been observed in those cases that are reported. In patients exposed several times there is no evidence that several exposures over a short period are associated with jaundice of more rapid onset than when the patients are exposed over a long period. Unless reports of the latter are seriously underrepresented, however, the fact that 80)", described jaundice after multiple exposure within a period of less than 28 days suggests that the risk of jaundice may be greater in these circumstances. Analysis of an apparent relation between the ages of patients and the intervals between their last exposure to halothane and the onset of jaundice (table I) showed, in fact, no correlation between them.
Seven doctors each reported two cases of jaundice, one reported three cases, and one seven cases. Five of this cluster of seven patients were concentrated in one group table VII) , and these five and other patients with incomplete anaesthetic histories were not included in the analysis of time relationships which led to the fourth principal finding outlined above. Reporting by certain individual doctors is not thought to have influenced these findings to any important degree.
Other drugs used during the month preceding the last exposure to halothane or during the interval between that exposure and the onset of jaundice were considered. Phenothiazines had been used in 12 non-fatal cases and 12 fatal cases and blood transfusions had been used in seven non-fatal cases (including two in which phenothiazines were also used) and eight fatal cases. Other drugs not commonly associated with jaundice had been used less often and no consistent pattern of drug use was found. Of particular importance was that in 11 of the 15 patients to whom blood had been given the onset of jaundice was within the incubation period for viral hepatitis. In seven cases blood had been given less than 14 days before the onset of jaundice, and in four cases between 15 and 28 days, while in four cases the patient had been transfused one to three months before the onset of jaundice. The death rate is correlated with age, and it cannot be concluded with certainty that the apparent increase in death rate with increasing numbers of exposures is not due simply to the greater ages of patients so exposed.
In this series nine patients had had more than one episode of jaundice and invariably the onset of jaundice occurred at progressively shorter intervals after the second or subsequent exposure. One patient (case 115), however, was atypical. Jaundice occurred after the second (or possibly the third) exposure to halothane but did not recur after a subsequent exposure. The reappearance of an adverse reaction after rechallenge with a drug is often regarded as providing the strongest possible evidence of causal relationship, and there is no reason why this should not be true also of halothane. Simpson et al. (1971) stated that the various stigmata of hypersensitivity have not commonly been observed. In this series most of the reports were received in the form of simple case summaries abstracted, usually in very few words, on one of the committee's yellow reporting cards. In more than half of the cases followed up, however, the doctor volunteered the information that there had been pyrexial reactions to earlier anaesthetics for which quite often no cause could be found. Rash or eosinophilia was also mentioned in a few cases.
During the period under review an average of seven or eight* deaths were reported to the committee each year. Mushin et al. (1971) estimated that about 1,500,000 patients are anaesthetized with halothane each year in England and Wales. This accounts for over 8000 of all general anaesthetics, a proportion which must indicate a very high level of clinical acceptability. They also estimated that 7% (about 100,000) of them were exposed more than once within a month. Six or seven of the reported deaths occurred after exposure to more than one halothane anaesthetic within a month, and the reported death rate in these circumstances would thus be between six and seven deaths per 100,000. Deaths from infectious hepatitis (I.C.D. 070) and acute or subacute necrosis of the liver (I.C.D. 570) in England and Wales in the years 1964-72 are shown in table VIII together with an estimate for the combined risk of death from these causes in the general population. The average death rate in these years was 0-6 per 100,000. Thus the reported deaths after multiple exposures within a period of one month are equivalent to about 10 times the risk of death in any one year from infectious hepatitis and acute or subacute hepatic necrosis in the general population.
Since many of the reports were not followed up it is possible that some deaths, occurring after a report had been submitted to the committee, are not included in this analysis. It is also highly likely that the reports represent only a small proportion of the events that actually occur. The reporting of "clusters" of cases by individual doctors, mentioned above, suggests that similar clusters of cases occurring elsewhere may not have been reported. This series does not, for example, include any of the 11 cases (with six deaths) reported by Sharpstone et al. (1971) to have been seen in two centres in the United Kingdom between 1967 and 1970. It has been the general experience of the committee that even fatal or much publicized adverse reactions are seriously under-reported. Inman and Vessey (1968) , for ex-*Only three deaths in Scotland were reported during the nine-year period covered by this analysis.
ample, found that in spite of much publicity about the risk of thromboembolic disease among women using oral contraceptives only 15%' of women known to have been taking them when they died from thromboembolism during 1966 were notified to the Committee on Safety of Drugs.
The almost invariable use of nitrous oxide and thiopentone and the frequent use of other agents as an adjunct to anaesthesia with halothane raises the possibility that they too, when administered repeatedly without halothane, might be responsible for cases of jaundice. If this is so it is surprising that no reports have been received. It is impossible to investigate this hypothesis since every doctor reporting jaundice after anaesthesia included halothane in the list of anaesthetic agents used.
The main result of this analysis is the demonstration tha-t the interval between the last of a series of halothane anaesthetics and the onset of jaundice is significantly showter than the corresponding interval following a single exposure, suggesting that some forn of sensitivity may have been induced in certain patients who had been exposed to this agent previously. Only the anaesthetist is in a position to balance this risk against other possibly more common risks which may attend the use of an alternative to halothane. In planning a series of anaesthetics it may be prudent to reserve halothane for the one operation where its advantages may be greatest, but only if the alternative agents are as safe and effective as halothane has proved to be.
It may be concluded that while factors other than exposure to halothane may account for some of the reports there is strong evidence that repeated exposure, especially within a short period, increases the incidence of jaundice, and this in turn may be fatal.
